Skip to main content

Table 2 Baseline morphological and functional echocardiographic data in both groups

From: Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study

 

m-TOR group (n = 30)

Control group (n = 58)

P value

LAD (mm)

38.4 ± 5.5

39.5 ± 5.5

0.379

LVEDD (mm)

48.2 ± 5.4

49.7 ± 6

0.259

IVS (mm)

12.7 ± 2.4

13 ± 2.7

0.259

PWT (mm)

12.3 ± 2.2

12.1 ± 2.1

0.832

RWT

0.52 ± 0.1

0.51 ± 0.1

0.948

EF (%)

69.7 ± 6

71.5 ± 8

0.272

FS (%)

46 ± 8.5

43 ± 7

0.102

LVMI (g/m 2.7 )

62 ± 22

65 ± 17

0.471

LVH prevalence (%)

77

86

0.259

Peak E (cm/sec)

0.80 ± 0.2

0.73 ± 0.2

0.099

Peak A (cm/sec)

0.92 ± 0.3

0.7 ± 0.2

0.000

E/A ratio

0.92 ± 0.3

1.1 ± 0.4

0.014

DT (msec)

215.5 ± 89

236 ± 64

0.673

LVIRT (msec)

99.3 ± 23

100.6 ± 39

0.847

  1. Values are shown as mean ± SD or percentages.
  2. Abbreviations: LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; IVS, interventricular septal thickness; PWT, posterior wall thickness; RWT, relative wall thickness; EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; Peak E, peak early diastolic flow velocity; peak A, peak late diastolic flow velocity; E/A ratio, ratio of early to late diastolic flow; DT deceleration time of E wave; LVIRT, left ventricular isovolumetric relaxation time.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us